HLA-DRB1 and Pruritus: Among cutaneous irAEs, 102 patients with metastatic cancer who received ICIs treatment were significantly associated with HLA-DRB1*11:01 and pruritus (OR = 4.53, X2 1,95 = 9.45, P < 0.01) (29).